Method for treating inflammatory diseases
AssigneesMackay Memorial Hospital, GoldRed NanoBiotech CO., LTD.
InventorsHsueh-Hsiao WANG, Hung-I YEH, Hong-Shong CHANG
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a method for treating an inflammatory disease in a subject, including administering to the subject a therapeutically effective amount of a dihydrolipoic acid (DHLA) coated gold nanocluster about 0.1 to 20 nm in diameter. Also disclosed is a method for reducing the expression of a pro-inflammatory molecule in a cultured cell, including contacting the cultured cell with the said DHLA coated gold nanocluster. Still disclosed is a pharmaceutical composition that includes the present DHLA coated gold nanocluster. The pharmaceutical composition is useful for treating the inflammatory disease in the subject.
Claims14
A method for treating an inflammatory disease in a subject, comprising administering to the subject an effective amount of a dihydrolipoic acid (DHLA) coated gold nanocluster about 0.1 to 20 nm in diameter, wherein,
- the DHLA coated gold nanocluster consists of a gold nanocluster formed by a plurality of gold nanoparticles, and a plurality of DHLA coated on the gold nanocluster;
- and
- the administration of the DHLA coated gold nanocluster reduces the expression of vascular endothelial growth factor (VEGF), intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion protein-1 (VACM-1), P-selectin, plasminogen activator inhibitor-1 (PAI-1), von Willebrand factor (vWF), tumor necrosis factor alpha (TNF-α), interleukin-8 (IL-8), and/or interleukin-1β (IL-1β) in the subject.
A method for reducing the expression of a pro-inflammatory molecule in a cultured cell, comprising contacting the cultured cell with about 1 to 1,000 nM of a dihydrolipoic acid (DHLA) coated gold nanocluster about 0.1 to 20 nm in diameter, wherein,
- the DHLA coated gold nanocluster consists of a gold nanocluster formed by a plurality of gold nanoparticles, and a plurality of DHLA coated on the gold nanocluster;
- and
- the pro-inflammatory molecule is selected from the group consisting of vascular endothelial growth factor (VEGF), intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion protein-1 (VACM-1), P-selectin, plasminogen activator inhibitor-1 (PAI-1), von Willebrand factor (vWF), tumor necrosis factor alpha (TNF-α), interleukin-8 (IL-8), and interleukin-1β (IL-1β).
Dependencies are inferred from the claim text.